April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
New Alzheimer’s launches are all but ruled out, so projects from Lilly, Alynlam and Roche top 2022’s biggest hopes.
But further data do not shed much light on Onpattro’s chances in Apollo-B.
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
Sanofi reckons it has a universal haemophilia therapy on its hands – but first it needs to test a lower dose.
With phase 3 data approaching, it should soon become clear whether Bridgebio’s amyloidosis project really has an edge over Pfizer’s Vyndaqel.